Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.50 |
| ▸ | METAP2 | P50579 | 9/20 | 0.47 |
| ▸ | METAP1 | P53582 | 6/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4441935 | 1.00 | REN (0.50) | RENMETAP2METAP1CYP2D6BCHE | |
| SCHEMBL4433202 | 1.00 | REN (0.50) | RENMETAP2METAP1CYP2D6BCHE | |
| SCHEMBL9439332 | 0.84 | METAP2 (0.48) | RENMETAP2METAP1CYP2D6BCHE | |
| SCHEMBL3599048 | 0.81 | CYP2D6 (0.50) | RENMETAP2METAP1CYP2D6 | |
| SCHEMBL3599047 | 0.81 | CYP2D6 (0.50) | RENMETAP2METAP1CYP2D6 | |
| SCHEMBL27689737 | 0.81 | CYP2D6 (0.50) | RENMETAP2METAP1CYP2D6 | |
| SCHEMBL8577758 | 0.79 | CYP2D6 (0.41) | RENMETAP2METAP1CYP2D6BCHE | |
| SCHEMBL21690082 | 0.78 | REN (0.47) | RENMETAP2METAP1 | |
| SCHEMBL7151431 | 0.78 | REN (0.47) | RENMETAP2METAP1 | |
| SCHEMBL272993 | 0.78 | REN (0.47) | RENMETAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | VITAE PHARMACEUTICALS, INC. | 2009-07-23 | — | — | US | disclosed |
| WO-2007117557-A2 | DIAMINOPROPANOL RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186884-A1 | such as N-(3-amino-2-hydroxypropyl)-3-(1-(2-(2-ethylphenoxy)phenyl)-1-hydroxy-5-;methoxypentyl)piperidine-1-carboxamide, used for the treatment of cardiovascular disorders | DNPEP, ACE, DPEP1 | REN 13/4885METAP2 20/4885METAP1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.